Dirui Industrial Co., Ltd. (300396.SZ) engages in the research, development, production, and sale of in-vitro diagnostic instruments, reagents, and test strips primarily in China, with exports to Russia, Latin America, Southeast Asia, the Middle East, and Africa; its core products encompass urine analysis systems including the FUS-2000 hybrid urine dry chemistry and flow cytometry sediment analyzer and H-800 fully automated analyzer, biochemical analysis such as the CS-800 high-speed clinical chemistry analyzer, chemiluminescence immunoassay, gynecological secretion analysis, blood cell and hematology analysis with BF series analyzers, coagulation analysis, integrated laboratory solutions, veterinary diagnostics, molecular diagnostics, and SARS-CoV-2 testing products. Founded in 1992 and headquartered in Changchun, Jilin Province, the company operates as a high-tech enterprise controlled by China Resources Industrial Funds and serves medical institutions across domestic and international markets with a workforce of approximately 1,821 employees. Recent developments include the renewal of its medical device production license, ongoing refinements to production through lean manufacturing and modularization initiatives as outlined in its 2025 half-year report, active participation in global exhibitions such as Medlab Middle East 2024 to showcase lab automation technologies, and strategic adjustments amid China's equipment update policies under the "China Manufacturing 2025" framework to enhance inventory standardization, domestic sourcing, and supplier synergies.